tirzepatide discontinuation weight regain study Reparameterized semaglutide PD model fits loss data Tirzepatide withdrawal leads to 25%

These provide sustained energy and fiber without the blood sugar spikes that refined carbohydrates cause

Weight loss can restore ovulatory cycles in individuals with irregular periods due to obesity or polycystic ovary syndrome (PCOS)

Tirzepatide is the only licenced GLP-1/GIP co-agonist for obesity, with several more GLP-1/GIP co-agonists in development [15]

Simultaneously, GLP-1 receptor activation stimulates glucose-dependent insulin release from pancreatic beta cells, suppresses inappropriate glucagon secretion, slows gastric emptying, and promotes satiety through central nervous system pathways

Some patients find that slow, deep breathing or lying down in a cool, quiet space for 1015 minutes after injection day reduces nausea intensity

Understanding the relationship between tirzepatide and skin health helps clinicians provide evidence-based guidance